



AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph at page 16, lines 26-32, as follows:

The compositions containing the present adenoviruses or cocktails thereof can be administered for prophylactic and/or therapeutic treatments of neoplastic disease. In therapeutic application, compositions are administered to a patient already affected by the particular neoplastic disease, in an amount sufficient to cure or at least partially arrest the condition and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose" or "efficacious dose." Amounts effective for this use will depend upon the severity of the condition, the general state of the patient, the route of administration and the potency of the virus. ?

Please amend Table 2 on page 18 by adding the SEQ ID NO column, as follows:

Table 2.

Virus	Mutation	Primer sequences	<u>SEQ ID NO:</u>
ONYX-051	R240A	GTTATTATGAATGTAGCGTTTACTGGCCCC	<u>1</u>
		GGGGCCAGTAAACGCTACATTCATAATAAC	<u>2</u>
ONYX-052	T255A	GTTTTCCTGGCCAATGCCAACCTTATCCTACAC	<u>3</u>
		GTGTAGGATAAGGTTGGCATTGGCCAGGAAAAC	<u>4</u>
ONYX-053	H260A	CCAACCTTATCCTAGCCGGTGTAAAGCTTC	<u>5</u>
		GAAGCTTACACCGGCTAGGATAAGGTTGG	<u>6</u>
ONYX-054	C271A	GGGTTTAACAATACCGCCGTGGAAGCCTGG	<u>7</u>
		CCAGGCTTCCACGGCGGTATTGTAAACCC	<u>8</u>
ONYX-056	R281A	CGATGTAAGGGTTGCGGGCTGTGCCTTTTAC	<u>9</u>
		GTAAAAGGCACAGCCCGCAACCCTTACATCG	<u>10</u>
ONYX-057	G282A	GTAAGGGTTCGGGCCTGTGCCTTTTAC	<u>11</u>
		GTAAAAGGCACAGGCCCGAACCCTTAC	<u>12</u>
ONYX-058	A284A	GTAAGGGTTCGGGGCTGTTCTTTTACTGCTGCTGGAAGG	<u>13</u>
		CCTTCCAGCAGCAGTAAAAGGAACAGCCCCGAACCCTTAC	<u>14</u>
ONYX-059	F285L	GGTTCGGGGCTGTGCCTTATACTGCTGCTGGAAGGGG	<u>15</u>
		CCCCTTCCAGCAGCAGTATAAGGCACAGCCCCGAACC	<u>16</u>
ONYX-060	C288A	GGGCTGTGCCTTTTACTGCGCCTGGAAGGGGGTGGTGTG	<u>17</u>
		CACACCACCCCTTCCAGGCGCAGTAAAAGGCACAGCCC	<u>18</u>
ONYX-061	W289F	GCTGTGCCTTTTACTGCTGCTTTAAGGGGGTGGTGTGTCGC	<u>19</u>
		GCGACACACCACCCCTTAAAGCAGCAGTAAAAGGCACAGC	<u>20</u>
ONYX-062	W289A	GCTGTGCCTTTTACTGCTGCGCGAAGGGGGTGGTGTGTCG	<u>21</u>
		CGACACACCACCCCTTCGCGCAGCAGTAAAAGGCACAGC	<u>22</u>

ONYX-063	K290A	CTGCTGCTGGGCGGGGGTGGTG	<u>23</u>
		CACCACCCCGCCCAGCAGCAG	<u>24</u>
ONYX-064	R295A	TGGAAGGGGGTGGTGTGTGCCCCAAAAGCAGGGCTTC	<u>25</u>
		GAAGCCCTGCTTTTGGGGGCACACACCACCCCTTCCA	<u>26</u>
ONYX-065	K297A	GGTGGTGTGTGCGCCCGCAAGCAGGGCTTCAATTAAGAAATG	<u>27</u>
		CATTTCTTAATTGAAGCCCTGCTTGCGGGGCGACACACCACC	<u>28</u>
ONYX-066	K303A	CCAAAAGCAGGGCTTCAATTGCGAAATGCCTCTTTGAAAGGT G	<u>29</u>
		CACCTTTCAAAGAGGCATTTGCGCAATTGAAGCCCTGCTTTTGG	<u>30</u>
ONYX-067	E308A	CTTCAATTAAGAAATGCCTCTTTGCAAGGTGTACCTTGGGTAT CC	<u>31</u>
		GGATACCCAAGGTACACCTTGCAAAGAGGCATTTCTTAATTG AAG	<u>32</u>

Please amend Table 2 (cont.) on page 19 by adding the SEQ ID NO column, as follows:

ONYX-068	R309A	TCAATTAAGAAATGCCTCTTTGAAGCGTGTACCTTGGGTATCC TGTC	<u>33</u>
		GACAGGATACCCAAGGTACACGCTTCAAAGAGGCATTTCTTA ATTGA	<u>34</u>
ONYX-069	E317A	TACCTTGGGTATCCTGTCTGCGGGTAACTCCAGGGTGCG	<u>35</u>
		CGCACCCCTGGAGTTACCCGAGACAGGATACCCAAGGTA	<u>36</u>
ONYX-070	G318A*	TACCTTGGGTATCCTGTCTGAGGCTACCTCCAGGGTCCGCC	<u>37</u>
		GGCGGACCCTGGAGGTAGCCTCAGACAGGATACCCAAGGTA	<u>38</u>
ONYX-071	G318A-N	TACCTTGGGTATCCTGTCTGAGGCTAACTCCAGGGTGCGCC	<u>39</u>
		GGCGCACCCCTGGAGTTAGCCTCAGACAGGATACCCAAGGTA	<u>40</u>
ONYX-080	E421A	CTAAGATATTGCTTGAGCCGGCGAGCATGTCCAAGGTGAAC	<u>41</u>
		GTTACCTTGGACATGCTCGCCGGCTCAAGCAATATCTTAG	<u>42</u>
ONYX-081	K425A	GAGCCCGAGAGCATGTCCGCGGTGAACCTGAACGGGG	<u>43</u>
		CCCCGTTACAGTTACACGCGGACATGCTCTCGGGCTC	<u>44</u>
ONYX-082	D433A	GAACCTGAACGGGGTGTTTGCCATGACCATGAAGATCTGG	<u>45</u>
		CCAGATCTTCATGGTCATGGCAAACACCCCGTTCAGGTTC	<u>46</u>
ONYX-083	K440A	CCATGAAGATCTGGGCGGTGCTGAGGTAC	<u>47</u>
		GTACCTCAGCACCGCCAGATCTTCATGG	<u>48</u>
ONYX-084	R443A	GGAAGGTGCTGGCGTACGATGAGACC	<u>49</u>
		GGTCTCATCGTACGCCAGCACCTTC	<u>50</u>
ONYX-085	Y444A	GGAAGGTGCTGAGGGCCGATGAGACCCGC	<u>51</u>
		GCGGGTCTCATCGGCCCTCAGCACCTTC	<u>52</u>

Table 2, continued

* Onyx-070 had two amino acids changed: Gly 318 to Ala, and Asn 319 to Thr.